Léonello Cusan
49 works · 4,261 citations · h-index 32
Top works
- Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy
- DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role during Aging
- Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women
- Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
- Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women
- Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Prostatic Carcinoma
- Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial
- Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
- Treatment of hirsutism with the pure antiandrogen flutamide
- Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy
- Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
- Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women
- Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women
- Steroid glucuronides: Human circulatory levels and formation by LNCaP cells
- Neoadjuvant hormonal therapy: The Canadian experience
- Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer
- Prostate Specific Antigen and Prostatic Acid Phosphatase for Monitoring Therapy of Carcinoma of the Prostate
- Plasma levels of hydroxy‐flutamide in patients with prostatic cancer receiving the combined hormonal therapy: An LHRH agonist and flutamide
- Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy